India faces a significant challenge from antibiotic resistance, with over 300,000 deaths annually linked to resistant infections. Researchers are developing new drugs such as Enmetazobactam, which has received FDA approval, and Zaynich, currently in Phase 3 trials. Experts call for reform in prescription practices to combat the overuse of broad-spectrum antibiotics. The urgency for holistic approaches in healthcare to tackle this complex issue is emphasized, warning of a future where common infections could become untreatable.